Effect of NMN on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity
Randomized, Double-blind, Placebo-controlled Clinical Trial of Nicotinamide Mononucleotide on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Florent Herpin
- Phone Number: +33 3 80 68 05 06
- Email: florent.herpin@groupecen.com
Study Contact Backup
- Name: Laurent Laganier, PharmD
- Phone Number: +33 7 50 96 41 12
- Email: laurent.laganier@lgdfrance.com
Study Locations
-
-
-
Dijon, France, 21000
- CEN Nutriment
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Body Mass Index ranging from 20 to 28 kg/m2(bounds included);
- Body weight between of 70 kg to 100 kg (including limits);
- Able to provide written informed consent to participate;
- Having a moderate level of physical activity according to the Global Physical Activity Questionnaire (GPAQ);
- Having a sport practice involving endurance or split races (including collective or individual sports) or cycling.
- Agreeing not to change their physical activity habits throughout the study;
Exclusion Criteria:
- Having a mental state that does not allow them to give free and informed consent to participate in the study;
- Being taking regularly or have taken within the last month any medication or dietary supplement that may increase endurance, recovery, or physical capacity. In particular, the following drugs are strictly prohibited: beta-2 agonists such as salbutamol (Ventolin®), terbutaline (Bricanyl®), fenoterol (Berotec®), salmeterol (Serevent®) and formoterol (Foradil®) as well as corticosteroids;
- Having history of a recent (less than 3 months) lower extremity muscle injury;
- Presenting a depressive syndrome;
- Presenting, in the opinion of the investigator, any symptomatology, pathology or cardiovascular risk factors that are incompatible with the conduct of the study or with the performance of a stress test or that could influence the results of the study, and in particular: 1) an abnormal resting and/or stress ECG at the inclusion visit according to the investigator; 2) presence of abnormalities in the lipid balance (Total Cholesterol, Triglycerides, HDL, LDL), blood glucose, and/or hemodynamic parameters;
- Presenting an abnormal biological balance (Creatinine, Uric acid, Troponin, Alanine aminotransferase / Aspartate aminotransferase, Lactate dehydrogenase, Creatine Kinase, C-reactive protein, Transferrin, Bilirubin, Gamma Glutamyl transpeptidase, Cholesterol (EAL), Glycemia, Ionogram, Alkaline phosphatase );
- Being not be compliant with the constraints imposed by the protocol;
- Having an allergy or a contraindication to the components of the studied products;
- Being already involved in another clinical trial or being in the exclusion period of a previous clinical trial;
- Being unable to understand, speak and read French fluently;
- Being not affiliated with a health insurance company;
- Being vulnerable persons or persons deprived of liberty by a judicial or administrative decision;
- Consuming illegal psychotropic substances or having an alcohol consumption of more than 2 glasses of alcohol/wine per day.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: NMN 250
NMN tablet (250 mg)
|
Daily supplementation with NMN at 250 and 500 mg for 38 days in total
|
|
Experimental: NMN 500
NMN tablet (500 mg)
|
Daily supplementation with NMN at 250 and 500 mg for 38 days in total
|
|
Placebo Comparator: Placebo
NMN-free placebo tablet.
|
Daily supplementation with placebo for 38 days in total
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evolution of muscle recovery
Time Frame: before and after 21 and 38 days of treatment
|
Wingate Anaerobic Test (WANT) preformed post-endurance test (at 85% maximum aerobic speed)
|
before and after 21 and 38 days of treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in physical capacity
Time Frame: before and after 21 and 38 days of treatment
|
physical capacity evaluated during an endurance test (at 85% maximum aerobic speed) by the maximum duration (time limit)
|
before and after 21 and 38 days of treatment
|
|
Changes in cardiorespiratory recovery
Time Frame: before and after 21 and 38 days of treatment
|
Measurement of blood pressure and heart rate at rest and at intervals of several minutes after the endurance test (at 85% maximum aerobic speed)
|
before and after 21 and 38 days of treatment
|
|
Changes in the perception of the arduousness of the effort
Time Frame: before and after 21 and 38 days of treatment
|
evaluated by the Borg scale during the endurance test (at 85% maximum aerobic speed)
|
before and after 21 and 38 days of treatment
|
|
Changes in blood lactate levels before and after physical exercise
Time Frame: before and after 21 and 38 days of treatment
|
blood lactate levels before and after the endurance test (at 85% maximum aerobic speed)
|
before and after 21 and 38 days of treatment
|
|
Changes in the perception of the intensity of post-exercise muscle pain (cramps)
Time Frame: before and after 21 and 38 days of treatment
|
post-exercise muscular pain in evaluated using a 7 points numerical scale, 24, 48 and 72 hours after the endurance test
|
before and after 21 and 38 days of treatment
|
|
Changes in the body composition
Time Frame: before and after 21 and 38 days of treatment
|
fat mass, muscle mass, visceral fat, water mass determined by Bioelectrical Impedance Analysis (BIA)
|
before and after 21 and 38 days of treatment
|
|
Changes blood NAD+ levels
Time Frame: before and after 21 and 38 days of treatment
|
Evaluation of cellular NAD+ concentration in blood from baseline to the end of study
|
before and after 21 and 38 days of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Nadège PLAZA, MD, CEN Nutriment
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- C1598
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.